35

Revenue 2017

Symbicort

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Symbicort was produced by AstraZeneca and Astellas.

Pharma news in brief

The US Food and Drug Administration (FDA) has approved AstraZeneca's (AZ) inhaled asthma drug, Symbicort, for the long-term treatment of patients aged 12 or over - a year earlier than ... AZ plans to market Symbicort in the US in mid-2007. Shares in AZ

NHS Direct launches new Patient Support Programme

NHS Direct is working with AstraZeneca to provide a telephone review and follow-up programme for all patients who have been prescribed Symbicort Maintenance and Reliever Therapy (SMART) by their doctor. ... NHS Direct is working with Anglo-Swedish

FDA concerned over GSK asthma drug risk

With annual sales expected to be in the region of USD 1bn, Flutiform, if approved, would compete with Advair/Seretide and AstraZeneca's Symbicort (budesonide/ formoterol).

SkyePharma looks at options after bid approach

The drug could generate annual sales of more than $1bn (? 575m) and would rival GSK's Seretide and AstraZeneca's Symbicort if approved.

People, November, 2005

He currently directs the global programme for Symbicort and the UK programme for Zyprexa.

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology